Article
Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Frontiers in immunology - 1 Jan 2023
Xu Shengshan, Chen Xiguang, Fang Jianxiong, Chu Hongyu, Fang Shuo, Zeng Leli, Ma Hansu, Zhang Tianzhi, Chen Yu, Wang Tao, Zhang Xin, Shen Tao, Zheng Youbin, Xu Dongming, Lu Zhuming, Pan Yihang, Liu Yuchen
Abstract excerpt
Background: Solute carrier family 35 member A2 (SLC35A2), which belongs to the SLC35 solute carrier family of human nucleoside sugar transporters, has shown regulatory roles in various tumors and neoplasms. However, the function of SLC35A2 across human cancers remains to be systematically assessed. Insights into the prediction ability of SLC35A2 in clinical practice and immunotherapy response remains limited....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.